| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Methionine (MET) restriction (MR) has been shown to arrest cancer growth and sensitizes tumors to chemotherapy. -Many cancer cells rely heavily on exogenous methionine to sustain rapid growth and proliferation because they often have impaired methionine salvage pathways. -Methionine contributes to the synthesis of glutathione, a key antioxidant. (Methionine is a precursor of glutathione, a tripeptide that reduces reactive oxygen species.) -MR diets might influence the redox state of cancer cells, increasing oxidative stress and thereby leading to cell death in metabolically compromised tumor cells. -Proliferation and growth of several types of cancer cells are inhibited by MR, while normal cells are unaffected by limiting methionine as long as homocysteine is present. -Methionine restriction is effective when the non-essential amino acid, cysteine, is absent from the diet or media. methionine is the precursor for cysteine which is essential for the formation of GSH. -Malignant cells lack the enzyme required to recycle homocysteine therefore giving methionine restriction the capacity to alter cancer cells while maintaining normal, healthy cells. While vegan diets are typically low in methionine, some nuts and legumes (such as Brazil nuts and kidney beans) are rich in methionine. Foods to avoid for MR diet: Animal Proteins: -Red Meat (Beef, Pork, Lamb): -Poultry (Chicken, Turkey): -Fish and Seafood: -Eggs: Both the egg whites and yolks are protein rich. -Dairy Products: Milk, cheese, and yogurt Certain Plant Proteins: -Soy Products: -Legumes: Protein Supplements: Foods Lower in Methionine (Often Favorable on an MR Diet) Fruits & Vegetables: leafy greens, berries, apples, and citrus fruits. Grains & Cereals: rice, oats, and barley Nuts and Seeds: can vary in methionine content. Alternative Protein Sources: emphasize protein sources with a lower methionine-to-cysteine ratio.
|
| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 2268- | dietMet, | Methionine dependency and cancer treatment |
| - | Review, | Var, | NA |
| 2264- | dietMet, | Methionine restriction for cancer therapy: From preclinical studies to clinical trials |
| - | Review, | Var, | NA |
| 2263- | dietMet, | Methionine Restriction and Cancer Biology |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:292 Target#:1110 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid